Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Cohu, Inc. (COHU) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cohu, Inc. (COHU) - free report >>
Image: Bigstock
New Strong Sell Stocks for July 14th
Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:
Cohu, Inc. (COHU - Free Report) engages in the semiconductor test and inspection equipment, and printed circuit board test equipment businesses. The Zacks Consensus Estimate for its current year earnings has been revised 2.5% downward over the last 30 days.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.
Helen of Troy Limited (HELE - Free Report) designs, develops, imports, markets, and distributes a portfolio of consumer products. The Zacks Consensus Estimate for its current year earnings has been revised 11% downward over the last 30 days.
Cornerstone Building Brands, Inc. designs, engineers, manufactures, markets, and installs external building products. The Zacks Consensus Estimate for its current year earnings has been revised 7.9% downward over the last 30 days.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 7.3% downward over the last 30 days.
View the entire Zacks Rank #5 List.